NetworkNewsBreaks – InMed Pharmaceuticals Inc. (
Post# of 228
(Total Views: 304)
Posted On: 03/17/2022 4:13:46 PM
NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Makes Changes in Management
InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced changes in company leadership. According to the announcement, InMed chief financial officer Bruce Colwill is retiring, effective March 31, 2022; Colwill will serve as an advisor to the company through June 30, 2022, to ensure a smooth transition. The company has appointed Brenda Edwards as interim CFO while the company searches for a full-time replacement. Edwards has garnered more than 35 years experience to her new position, including more than two decades of experience as a chief financial officer; she has served in both private and public companies. Throughout her career, she has worked closely with merger and acquisitions, financings, managing high-growth situations and financial reporting. “I would like to thank Bruce for his invaluable leadership and significant contributions over almost three years including managing our transition to the Nasdaq and several financings to ensure the long-term growth of the company,” said InMed president and CEO Eric A. Adams in the press release. “I wish him the very best and appreciate his continued assistance to ensure a smooth transition. I am delighted to welcome Brenda to the company. Brenda comes with extensive experience and will be an excellent fit to help us through this transitional period.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has announced changes in company leadership. According to the announcement, InMed chief financial officer Bruce Colwill is retiring, effective March 31, 2022; Colwill will serve as an advisor to the company through June 30, 2022, to ensure a smooth transition. The company has appointed Brenda Edwards as interim CFO while the company searches for a full-time replacement. Edwards has garnered more than 35 years experience to her new position, including more than two decades of experience as a chief financial officer; she has served in both private and public companies. Throughout her career, she has worked closely with merger and acquisitions, financings, managing high-growth situations and financial reporting. “I would like to thank Bruce for his invaluable leadership and significant contributions over almost three years including managing our transition to the Nasdaq and several financings to ensure the long-term growth of the company,” said InMed president and CEO Eric A. Adams in the press release. “I wish him the very best and appreciate his continued assistance to ensure a smooth transition. I am delighted to welcome Brenda to the company. Brenda comes with extensive experience and will be an excellent fit to help us through this transitional period.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)InMed Pharmaceuticals, Inc. (INM) Stock Research Links
Scroll down for more posts ▼